Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Allison Berger"'
Autor:
Akito Nakamura, Stephen Grossman, Keli Song, Kristina Xega, Yuhong Zhang, Donna Cvet, Allison Berger, Gary Shapiro, Dennis Huszar
Publikováno v:
Blood. 139(18)
Small ubiquitin-like modifier (SUMO) is a member of a ubiquitin-like protein superfamily. SUMOylation is a reversible posttranslational modification that has been implicated in the regulation of various cellular processes including inflammatory respo
Autor:
Maria Patra-Kneuer, Stefan Steidl, Akito Nakamura, Andrea Polzer, Stephen Grossman, Igor Proscurshim, Carmen Ginzel, Keli Song, Christina Heitmüller, Allison Berger
Publikováno v:
Blood. 138:2268-2268
Introduction TAK-981 is a first-in-class small molecule inhibitor of the SUMO activating enzyme currently in Phase I/II clinical trials. TAK-981 has been shown to increase NK cell activation and M1 macrophage polarization via upregulation of Type I i
Autor:
Lili Wang, Xiaoguang Wang, Tanya Siddiqi, Allison Berger, Alexey V. Danilov, Dan Vuong, Vi Lam, Olga V. Danilova, Tingting Liu
Publikováno v:
Blood. 138:2414-2414
Introduction: Immune checkpoint inhibitors have limited single agent activity in B-cell non-Hodgkin lymphoma (NHL). Hence, it is important to develop strategies which will thwart immune evasion in this disease. Neddylation is a sequential enzyme-base
Autor:
Shaji Kumar, Jeremy T. Larsen, Saulius Girnius, Rafat Abonour, Igor Proscurshim, Omar Nadeem, Akito Nakamura, Yuhong Zhang, Keli Song, Stefano R. Tarantolo, Vivek Roy, Meera Mohan, Moshe Yair Levy, Allison Berger, Deborah Berg, Cara A. Rosenbaum, Sagar Lonial, Ralph V. Boccia, Habte A. Yimer, Bo Chao, Christine K. Ward
Publikováno v:
Blood. 138:2742-2742
Background: SUMOylation, a post-translational modification analogous to ubiquitination, attaches a small, ubiquitin-like modifier (SUMO) to target proteins. SUMOylation plays a central role in the immune system by regulating type I interferon (IFN-I)
Autor:
Alejandro Gomez-Pinillos, Alonzo Martinez, Allison Berger, Amitkumar Mehta, Deborah Berg, Stephane Doucet, Paolo Caimi, Tycel Phillips, Lapo Alinari, Brenda W. Cooper, Bo Chao, Christine K. Ward, Igor Proscurshim, John Gibbs, Sarit Assouline, Alexey V. Danilov, Sharon Friedlander, Steven I. Park
Publikováno v:
Blood. 138:2488-2488
Background: TAK-981 is the first small-molecule inhibitor of SUMOylation to enter clinical trials. SUMOylation is a post-translational modification in which small ubiquitin-like modifier (SUMO) proteins are activated and covalently attached to substr
Autor:
Kathryn A. Rizzo, Steven Grant, Sri Lakshmi Chalasani, Lawrence F. Povirk, Liang Zhou, Yun Dai, Mohamed Rahmani, Allison Berger, Andrea Ferreira-Gonzalez, Lihong Li, Hui Lin, Catherine I. Dumur, Yun Leng, Shuang Chen, Maciej Kmieciak, Yu Zhang
Publikováno v:
Blood. 127:2219-2230
Two classes of novel agents, NEDD8-activating enzyme (NAE) and histone deacetylase (HDAC) inhibitors, have shown single-agent activity in acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS). Here we examined mechanisms underlying interact
Autor:
Alexey V. Danilov, Taylor Hashiguchi Rowland, Allison Berger, Adam Kittai, Scott R Best, Vi Lam, Nur Bruss, Tingting Liu
Publikováno v:
Blood. 134:4313-4313
Introduction: Inhibitors of B-cell receptor associated kinases (e.g., Bruton tyrosine kinase and phoshpoinotiside-3 kinase) have led to significant improvement in outcomes of patients with CLL. Furthermore, such therapies have immunomodulatory effect
Autor:
Dennis Huszar, Allison Berger, Alejandro Gomez-Pinillos, Mi-Sook Kim, Amitkumar Mehta, Igor Proscurshim, Chirag Patel, Paolo Caimi, Bingxia Wang, Sarit Assouline, Sharon Friedlander
Publikováno v:
Blood. 134:1593-1593
Background TAK-981 is a first-in-class, small molecule inhibitor of SUMOylation, a reversible post-translational modification that regulates protein function by covalent attachment of small ubiquitin-like modifier (SUMO) proteins to a protein substra
Autor:
Fazal Shirazi, Marc L. Hyer, R. Eric Davis, Isere Kuiatse, Hans C. Lee, Vaishali Shinde, Allison Berger, Hua Wang, Junling Zhuang, Sakeena Syed, Zhiqiang Wang, Zuzana Berkova, Robert Z. Orlowski, Richard J. Jones, Nibedita Chattopadhyay, Judy Qiuju Shi, Jie Yu, Stephen Tirrell, Ram Kumar Singh
Publikováno v:
Blood. 133(14)
Three proteasome inhibitors have garnered regulatory approvals in various multiple myeloma settings; but drug resistance is an emerging challenge, prompting interest in blocking upstream components of the ubiquitin-proteasome pathway. One such attrac
Autor:
Nur Bruss, Allison Berger, Cody Paiva, Stephen E. Spurgeon, Taylor Rowland, Scott R Best, Alexey V. Danilov
Publikováno v:
Blood. 132:1867-1867
Introduction: Despite the promise of B-cell receptor-associated kinase inhibitors (BCRi) in CLL, resistance to these agents is inevitable. Ubiquitin-proteasome systems are altered in cancer, leading to destabilization of tumor suppressors, overexpres